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NONINVASIVE PREDICTOR OF OESOPHAGEAL VARICES IN CIRRHOSIS- 
PLATELET COUNT/SPLEEN DIAMETER RATIO 
Ashwini kamath; S. Muthukumaran; K.Nagarajan; Department of Internal Medicine, Thanjavur medical 
college and hospital,Thanjavur 
ABSTRACT: 
BACKGROUND:  Current guidelines recommend that all cirrhotic patients must 
undergo screening endoscopy for the presence of oesophageal varices. With 
increasing number of patients with chronic liver disease and their improved 
survival, these guidelines impose a burden on the endoscopic units, available 
facilities and also economically. In this study we aim to identify the value of 
Platelet count/Spleen diameter ratio as a non invasive predictor of oesophageal 
varices in patients with cirrhosis and its predictive efficacy.  
 MATERIALS AND METHODS:  60 patients with newly diagnosed cirrhosis 
admitted during a one year study period were evaluated prospectively. Patients 
with unstable vitals at admission, bleeders and history of prior treatment (medical 
or surgical) were excluded. All patients underwent biochemical work up, UGI 
scopy and ultrasonographic measurement for spleen diameter. Platelet count/spleen 
diameter ratio was calculated for all patients. 
 
 RESULTS:  Platelet count/spleen diameter ratio was found to be significantly 
different in patients with oesophageal varices and in those without. At a cutoff of 
909, it had a sensitivity of 95.2% and specificity of 88.8%. Prevalence adjusted 
positive predictive value of the test was found to be 95% and negative predictive 
value of 89%. It also correlated significantly with other non invasive parameters 
such as ascites, platelet count, splenomegaly and Child-Pugh score. 
CONCLUSION: Platelet count/spleen diameter is valuable tool in non invasive 
prediction of oesophageal varices in patients with cirrhosis. Its use would avoid 
unnecessary endoscopy without a significant risk of missing oesophageal varices. 
 1 
INTRODUCTION 
           Oesophageal varices are one of the most common complications of 
portal hypertension that accompanies liver cirrhosis. The prevalence of 
oesophageal varices may range from 60% to 80% in patients with cirrhosis, 
and the reported mortality from variceal bleeding is around 17% to 57%
1-4
. 
 
The Baveno III Consensus Conference on portal hypertension 
recommends that all patients with cirrhosis should undergo endoscopic 
evaluation for varices at the time of diagnosis
5
. To evaluate the progression 
of this feature, it has been proposed to repeat endoscopy in patients with no 
varices every 2-3 years and every 1-2 years in patients with small varices
6
. 
 
In a developing nation like ours where there is a relative lack of 
endoscopy units, the practicality of these guidelines is questionable. 
Moreover, they impose an additional burden on the available facilities and 
also economically. 
 
In order to reduce this increasing burden many studies have attempted 
to identify non-invasive parameters to help predict the presence of any 
Oesophageal Varices. Parameters like spider angiomata
7
, splenomegaly
8, 9
, 
ascites
9, 10
, prothrombin time/activity
7, 11
(PT-INR), serum albumin
12
, platelet 
 2 
count
7-12
, Platelet count/Spleen diameter Ratio
1, 13, 14
 (PSR) have been shown 
as independent predictors for the presence of oesophageal varices. Hence 
this study was conducted to study the value of PSR as a non invasive 
predictor of oesophageal varices in patients with cirrhosis and its predictive 
efficacy.  
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AIMS AND OBJECTIVES OF THE STUDY 
 
1. To identify Platelet Count/Spleen Diameter ratio as a non invasive index 
in predicting the presence of oesophageal varices in patients with 
cirrhosis. 
2.  To assess the Predictive value of Platelet Count/Spleen Diameter ratio 
in the non invasive diagnosis of oesophageal varices in cirrhotic 
patients. 
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REVIEW OF LITERATURE 
CIRRHOSIS: EPIDEMIOLOGY AND DIAGNOSIS
 
End stage of chronic damage to the liver is cirrhosis, characterized by 
fibrosis resulting in destruction and distortion of normal liver architecture
15
. 
Functional liver tissue is destroyed and replaced by regenerating nodules 
that cannot cope with the normal liver functions. As the progressive cascade 
of liver tissue destruction continues relentlessly, the patient shows signs and 
symptoms of liver cell failure. Such a patient shows reduced physical, 
mental, biochemical functions, the final result of the process leading to 
complete liver cell failure and death.  
 
CAUSES OF CIRRHOSIS: 
Numerous infectious, chemical, autoimmune, hereditary and vascular 
factors have been implicated in the causation of chronic liver injury leading 
to cirrhosis. 
Viral hepatitis 
  Hepatitis A infection is usually a nonfatal, self-limited disease where 
a short period of disability is followed by complete recovery. Acute liver 
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cell failure is of rare occurrence. Though when it does occur, it is usually 
sub massive necrosis without cirrhosis characterized by complete collapse 
of liver architecture. 
Similar to hepatitis A, hepatitis E is a self-limited process. Though it 
does not contribute to cirrhosis, it may manifest as an acute fulminant 
hepatic failure in pregnant patients in their third trimester. 
Unlike the other hepatotrophic viruses, Hepatitis B virus is a DNA 
virus.  It may occur as an isolated entity or as a co infection with hepatitis D 
virus (delta infection) 
15
. The presence of Hepatitis B infection is necessary 
for the infectivity of Hepatitis D, but the reverse is not true.  Chronic 
hepatitis B infection may lead to cirrhosis and Hepatocellular carcinoma 
(HCC). There is an increased incidence of this infection in Asia and sub-
Saharan Africa. The mortality rate is 16% for those with compensated 
disease and 65% to 86% for decompensated disease
16
. In untreated 
individuals with HBeAg positive chronic hepatitis B, the incidence of 
cirrhosis is from 2 to 5.4 per 100 person years with an estimated 5-year 
cumulative risk of 8% to 20% 
17
. Predictors of progression to cirrhosis and 
mortality include persistent viral replication and older age. The presence of 
any other independent hepatotoxic factors like alcoholism, HCV co-
infection may also contribute to progression to liver cell failure. In the 
EUROHEP cohort study, the cumulative incidence of hepatic 
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decompensation was 16% and the mean interval between the time of 
diagnosis of cirrhosis to the first episode of decompensation was 31 
months
16, 17
. Survival dropped over 55% at 1 year and to 14% to 28% at 5 
years following hepatic decompensation. 
Hepatitis C virus may cause cirrhosis in 15% of patients and chronic 
infection in up to 80%
18
. The propensity to cirrhosis and HCC in hepatitis C 
infection is increased in patients who are also alcoholics.  
While hepatitis A and B are vaccine-preventable infections, no 
vaccines are available for the prevention of hepatitis C, D or E infections 
Alcohol 
Alcohol is an important and common cause of liver disease and 
cirrhosis worldwide. Heavy alcohol intake may lead to cirrhosis in 1 to 2 
years or may even manifest several years after cessation of the habit. Just as 
cigarette lung damage is measured in pack years, pint years can be used to 
measure alcohol damage, with 15 pint years being a reliable measure for 
cirrhosis (1 pt of whiskey per day for 15 years)
19
.  
Identified risk factors: 
 Quantity of alcohol: consumption of 60–80g per day (approximately 
75–100 ml/day) for 20 years or more in men, or 20g/day 
 7 
(approximately 25 ml/day) for women elevates the risk of liver 
disease by 7 to 47%
18
 
 Drinking pattern: drinking outside of meal times increases the risk of 
ALDs by 2.7 times
20
 
 Gender: females are more susceptible to alcohol mediated liver 
disease. Shorter duration and doses of chronic alcoholism is 
associated with development of ALD.
20
 
 Hepatitis C infection: concomitant hepatitis C infection is known to 
significantly accelerate the cirrhotic process
20
 
 Genetic factors: Monozygotic twins are more likely to be alcoholics 
and to develop liver cirrhosis than dizygotic twins. Polymorphisms in 
the enzymes involved in the alcohol metabolism, such as alcohol 
dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), 
CYP4502E1, mitochondrial dysfunction, and cytokine polymorphism 
may play a role in genetic component. However, no specific 
polymorphisms have been currently firmly linked to ALD. 
 Haemochromatosis(iron overload states) 
 Diet: Alcoholics are usually malnourished due to lack of adequate 
nutritious diet and anorexia. This predisposes them to malnutrition, 
particularly vitamin A and E deficiency. This is significant as 
alcohol-induced liver damage may be aggravated by preventing 
regeneration of hepatocytes.
20
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Schematic representation of pathogenesis of alcohol mediated liver injury 
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Nonalcoholic fatty liver disease 
There is an epidemic of obesity in adults and children in India and 
many other developed countries. Many of these may have nonalcoholic fatty 
liver disease (NAFLD) encompassing nonalcoholic steatohepatitis (NASH), 
which may progress to fibrosis and cirrhosis. Since this is an emerging 
entity, cirrhosis previously branded as „cryptogenic‟ may actually have been 
secondary to NASH. The only valued treatment at present is weight 
reduction along with correction of lipid and glucose abnormalities. The 
changing trends of the modern era with its sedentary lifestyle and food 
faddism, the numbers of patients with obesity is on the rise. Thus more 
patients will progress to cirrhosis at an earlier age in the future.
21, 22
 
Biliary cirrhosis
 
The pathological features of biliary cirrhosis differentiate it from post 
viral or alcoholic hepatitis, yet the manifestations of end stage liver disease 
are the same. Histopathological features are those of chronic cholestasis, 
xanthomatous transformation of hepatocytes, copper deposition and the 
irregular so-called biliary fibrosis. 
  Primary biliary cirrhosis (PBC), a disorder that often affects middle-
aged women, is characterized by portal inflammation and necrosis of 
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cholangiocytes of small and medium sized bile ducts. Laboratory work up 
shows cholestatic liver enzyme abnormalities and positive antimitochondrial 
antibodies (AMA) 
22
. 
On the other hand, Primary sclerosing cholangitis (PSC) typically 
affects young men. It is a chronic cholestatic condition occurring due to the 
diffuse inflammation and fibrosis of the entire biliary tree, the etiology of 
which remains unknown. Over 50% patients with PSC may have ulcerative 
colitis.
22
 There is no specific serologic marker, perinuclear antineutrophil 
cytoplasmic antibody (pANCA)  may be positive in up to 65%. The 
diagnosis is made by a “pruned tree” deformity of bile ducts on endoscopic 
retrograde cholangiopancreatography or magnetic resonance 
cholangiopancreatography. 
Autoimmune causes 
Autoimmune hepatitis, has unknown etiology and may cause 
progressive liver dysfunction.
23
 The presence of antinuclear antibodies, anti-
smooth muscle antibodies and increased serum gamma globulins aids in 
diagnosis. Typically these patients do not benefit from immunosuppressive 
medications such as steroids and azathioprine- wherein the disease is called 
„burned out‟. Other autoimmune disorders such as Sjögren syndrome, 
thyroiditis, glomerulonephritis, ulcerative colitis, celiac disease and juvenile 
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diabetes mellitus may be associated with an increased frequency in these 
patients. 
Genetic disorders 
The genetic diseases implicated in liver cirrhosis are 1-antitrypsin 
deficiency, Wilson disease, and Hemochromatosis. Screening of all family 
members becomes mandatory when these disorders are diagnosed in any 
one among the family. 
Cirrhotic patients with emphysema and children with cholestasis 
should be evaluated for 1-antitrypsin deficiency.
24
 Patients with ZZ 
phenotype are at greater risk of developing liver disease. Diagnosis is made 
by estimation of 1-antitrypsin levels and phenotype. Liver biopsy shows 
characteristic periodic acid Schiff (PAS) positive, diastase resistant 
globules. Liver transplantation is the only effective and curative treatment 
available. 
Wilson‟s disease is an autosomal recessive disorder and is 
characterized by mutation in ATP7B gene. Deficiency of this protein 
impairs biliary copper excretion thereby causing hepatic copper 
accumulation and oxidant damage secondary to copper toxicity. Young 
patients presenting with abnormal liver function tests, psychiatric and 
neurologic findings should be evaluated to exclude Wilson‟s.25 Diagnosis 
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may be confirmed by 24-hour urine copper excretion, slit-lamp examination 
for Kayser-Fleischer rings and by liver copper quantification. Prompt 
treatment with zinc and/or trientine is advocated to prevent progression of 
disease. 
Hereditary hemochromatosis characterized by hepatic iron 
accumulation is an inborn error of iron overload. It results in liver, cardiac, 
pancreatic, and joint dysfunction. Hepatic iron deposition leads to portal 
based fibrosis which may progress to cirrhosis and HCC.  Iron studies in 
these patients reveal elevated transferrin saturation and high serum ferritin 
levels.
26
 HFE mutation testing usually confirms the diagnosis. Therapeutic 
phlebotomy is the treatment of choice. Causes of secondary 
hemochromatosis are alcoholism, thalassemia major, multiple transfusions 
etc which may also progress to chronic liver disease. 
Rare causes:
 
Infections: schistosomiasis, syphilis 
Metabolic disorders: mucopolysaccharoidosis, glycogen storage disorders 
Drugs: -Methyldopa, Methotrexate, Amiodarone, Nitrofurantoin, 
Hypervitaminosis A 
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Miscellaneous: Sarcoidosis, Graft-versus-host disease, Budd-Chiari 
syndrome, chronic congestive heart failure (cardiac cirrhosis), chronic 
ductal obstruction (secondary biliary cirrhosis) 
 
CLINICAL FEATURES: 
The clinical picture of cirrhosis unfolds with progressive liver cell 
loss and dysfunction. It is characterized by the following features: 
 Jaundice/Icterus - cutaneous and scleral yellowing due to 
inability of the liver to clear bilirubin.  
 Spider angiomas/naevi- superficial spider-like cluster of 
capillaries composed of a central „feeder‟ vessel and multiple 
minute tortuous and dilated radiating vessels with a peripheral 
erythema  
  Bruising, subcutaneous ecchymosis, bleeding- decreased 
synthesis of clotting factors and low platelet counts. 
 Muehrcke nails-  nails with paired horizontal white bands 
 Terry nails- nails with whitening of the proximal two thirds and 
reddening of the distal third.  
 Digital clubbing.  
 14 
 Dupuytren‟s contracture- thickening of the palmar fascia, 
especially in alcoholics. 
 Palmar erythema, gynecomastia, decreased body hair and 
testicular atrophy- due to elevated levels of estrogen in men. This 
contributes to decreased libido and infertility. 
 Amenorrhea, breast atrophy and infertility in women 
 Fetor hepaticus- a sweet odor in the breath of patients owing to 
decreased clearance of mercaptans.  
 Parotid gland enlargement- painless swelling of the gland in the 
absence of obstruction of the Stensen‟s duct. 
  Asterixis- flapping tremors or liver flap, occur with increasing 
blood ammonia levels.  
 Altered mentation and coma- decreased toxin clearance by the 
dysfunctional liver. 
 Enlarged, tender liver may be palpated but more often, the organ 
is difficult to palpate because of fibrosis and shrunken state. This 
scarred organ causes resistance to blood flow and therefore, 
portal hypertension. 
 15 
 
 Splenomegaly- due to portal hypertension and congestion. 
  Varices (gastric and oesophageal) - Blood flow collateralizes 
into the gastric and esophageal venous system causing dilation of 
the veins.  
 Hematemesis – rupture of the varices beyond a critical venous 
pressure. Major bleeds maybe life threatening.  
 colonic varices and hemorrhoids- back pressure in portal system 
 caput medusa- portosystemic collaterals around the umbilicus  
 Ascites- increased shunting of pressure into the splanchnic 
circulation leads to shift of fluid into the abdomen, lower 
extremities, scrotum, or vulva. This is aggravated by 
hypoalbuminemia related to decrease hepatic protein synthesis. 
The risk of infection is also increased- spontaneous bacterial 
peritonitis (SBP). The presence of ascites is associated with a 
50% survival at 2 years. 
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DIAGNOSIS: 
The diagnosis of liver cirrhosis may remain elusive despite a 
thorough non invasive work up as there is no single biochemical or 
radiological parameter that correlates with specific liver injury or the extent 
of inflammation and damage. A combination of biochemical, radiological, 
clinical aids and histology are usually required. Invasive diagnosis through 
liver biopsy is the only definitive marker of progression to cirrhosis. 
Biochemical Markers of Cirrhosis 
As mentioned in the earlier text, there is no single biochemical 
marker of cirrhosis. A conventional liver function test (LFT) is usually 
initiated when signs and symptoms are present or when the stigmata of 
chronic liver disease are apparent. LFT comprises of alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), fractionated 
bilirubin, alkaline phosphatase, prothrombin time (PT), and serum albumin 
estimation. 
The AST, ALT, bilirubin, and alkaline phosphatase are not true 
indicators of hepatic function. AST and ALT are liver enzymes released into 
the circulation from damaged hepatocytes after hepatic injury. ALT is a 
cost-effective screening test for hepatic inflammation although it serves a 
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limited role in predicting the extent of inflammation and has no proven role 
in predicting the severity of fibrosis.
 27
 
The AST/ALT ratio is around 0.8 in normal subjects. In alcoholic 
hepatitis, the ratio is greater than 2:1.
28
 In patients with NASH, the ratio is 
typically less than 1 and rises to greater than 1 with rising fibrosis score.
29
 In 
these studies, AST/ALT ratio of more than 1 had a specificity of >75% and 
sensitivity of 32% to 83% for cirrhosis.
 29
 However, 2 additional studies 
failed to corroborate the predictive value of the AST/ALT ratio, and hence 
the clinical utility of this ratio remains unclear.
 30
 
The PT and serum albumin are accurate markers of hepatic synthetic 
function. A normal prothrombin time is maintained by the hepatic synthesis 
of clotting cascade proteins. With progression to fibrosis, the ability of the 
cirrhotic liver to synthesize these proteins diminishes leading to 
prolongation of PT. The PT helps predict survival in cirrhotics when used as 
a parameter in the Child-Pugh classification or model for end-stage liver 
disease (MELD) score. In a study by Croquet V., Vuillemin E., Ternisien 
C., et al, the PT consistently and accurately correlated with the degree of 
fibrosis of liver.
31
 However, it is not specific marker for hepatic dysfunction. 
Disorders such as inherited coagulopathies, malabsorption syndromes and 
malnutrition can also account for abnormal clotting profiles. 
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Albumin which is also exclusively synthesized in the liver may also 
decrease with progression of liver disease. Similar to the PT, it is used in the 
Child-Pugh classification in determining the prognosis. Noncirrhotic 
conditions such as malnutrition, intestinal malabsorption and renal disease 
may also cause hypoalbuminenia. Low serum albumin also contributes to 
ascites and increases the risk of infections in cirrhosis. 
 Platelet count of less than 150,000 is defined as thrombocytopenia, 
which is a common finding in chronic liver disease. Platelet count of 
50,000–75,000 may be found in approximately 13% of patients with 
cirrhosis.
32
 Passive sequestration of platelets in the spleen has been 
implicated in the causation of thrombocytopenia in cirrhosis. However, 
recent research suggests impaired platelet production, increased destruction 
and functional disorders may also contribute to thrombocytopenia.  Pilette 
C., Oberte F., Aube C., et al demonstrated the diagnostic accuracy of 
platelet count of< 1 60 000/l in prediction of large varices. It had a 
sensitivity of 80% and a specificity of 58%. Platelet count ≥260 000/L has a 
negative predictive value ≥91%.7 
A multitude of combinations of biochemical markers have been 
proposed to increase the accuracy of diagnosing cirrhosis. These include the 
PT, gamma-glutamyl transpeptidase activity, FIB-4, Fibro test and serum 
apolipoprotein A1 concentration (PGA) index.  
 19 
Progressive hepatic fibrosis is characterized by alteration in the 
extracellular matrix of the hepatic parenchyma
22
. Hence products of 
collagen synthesis, cytokines, chemokines and enzymes involved in 
fibrogenesis may be used as direct markers of liver fibrosis. Examples 
include procollagen peptide, laminin, matrix metalloproteinase, type IV 
collagen, transforming growth factor β, and hyaluronic acid. In spite of the 
remarkable progress made in direct, non invasive diagnosis of cirrhosis, 
their introduction has not eliminated the need for biopsy. Once the diagnosis 
of cirrhosis has been established, serologic and biochemical markers maybe 
be used for specific etiologic diagnosis (Table 1)
15
.  
 
Table 1   -- Biochemical and histological markers of causes of cirrhosis 
Etiology Biochemical Markers Characteristic Histological Findings 
ALD AST/ALT >2 
Elevated GGT 
Mallory bodies 
Giant mitochondria 
Centrilobular fibrosis 
Ballooned hepatocytes 
1-Antitrypsin deficiency Decreased 1-antitrypsin 
Pi type ZZ or SZ 
Eosinophilic globules in periportal 
zones 
Periodic acid–Schiff deposits 
Autoimmune hepatitis Positive ANA titer 
Positive ASMA titer 
Positive LKM Ab 
Lymphoid aggregates 
Prominent plasma cells 
Interface hepatitis 
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Etiology Biochemical Markers Characteristic Histological Findings 
Elevated globulins 
(especially serum IgG) 
Rosetting of hepatocytes 
(Duct damage) 
Hepatitis B Positive HbsAg ± eAg 
positivity 
Positive HepB DNA 
Elevated ALT, AST 
Ground glass cells containing HBsAg 
Hepatitis C Positive HCV Ab 
Positive HCV RNA 
Elevated ALT, AST 
Bile duct damage 
Lymphocyte infiltration 
Hereditary 
hemochromatosis 
Fasting transferrin 
saturation >45% 
Elevated ferritin 
HFE gene mutation 
Iron deposition within hepatocytes 
Primary biliary cirrhosis Positive AMA 
Elevated serum IgM 
Loss of interlobular ducts 
Ductal inflammation 
“Florid duct” lesion 
Granulomas 
Primary sclerosing 
cholangitis 
Elevated p-ANCA Bile duct scarring 
Concentric (“onion-skin”) fibrosis 
Wilson disease Ceruloplasmin <18 
24-h urinary copper 
excretion >100 mcg 
Copper deposits 
Focal, may be missed on biopsy 
Mallory bodies 
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Radiologic Findings in Cirrhosis
15 
No specific radiologic test can diagnose cirrhosis. Abdominal 
ultrasound, CT, and MRI are most useful in supporting the clinical or 
histological findings of cirrhosis. They identify manifestations such as 
hepatomegaly, hepatic nodularity, ascites, portal hypertension, portal 
vein thrombosis, portosystemic collaterals or varices and HCC. 
Abdominal ultrasound is the most common and the first imaging 
modality used to evaluate cirrhosis. It is not only inexpensive but the 
results are easily reproducible and pose no risk of radiation or contrast 
exposure. A coarsened, heterogeneous echo pattern with surface 
nodularity on ultrasound characterizes a cirrhotic liver. Liver may 
appear atrophic in advanced disease. Caudate lobe hypertrophy is 
common. Sonographic ratio of caudate lobe width to right lobe width of 
0.65 or more was demonstrated to have a sensitivity and specificity of 
84% and 100%, respectively in diagnosis of cirrhosis as per a study by 
Harbin W., Robert N., Ferrucci J.
33
Portal hypertension is diagnosed by 
the presence of splenomegaly, ascites, and portosystemic collateral 
vessels on ultrasound. Doppler sonography can further identify 
thrombosis of portal and hepatic veins, dilatation of hepatic artery, 
portal vein and superior mesenteric vein. The reversal of normal portal 
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flow towards the liver, known as hepatofugal flow can be detected by 
color Doppler ultrasound. 
 
Parenchymal distortion by cirrhotic process produces characteristic 
changes which can be easily recognized on contrast-enhanced CT and 
MRI. These changes are nodular liver margin, hypertrophy, atrophy of 
liver and fibrosis induced heterogeneity, steatosis, and iron deposition.  
 
The radiologic changes become easier to identify as advanced 
disease sets in.  Portal venous phase CT and magnetic resonance 
angiography can also detect portal vein thrombosis and flow, although 
these studies are expensive and provide no additional information over the 
convectional ultrasound with Doppler.  
 
Histological Patterns of Cirrhosis 
Liver biopsy is the gold standard in diagnosis of cirrhosis, the 
sensitivity and specificity ranging from 80% to 100%. Biopsy also aids in 
management and prognosis as it serves to grade and stage the severity of 
fibrosis. However, percutaneous transabdominal liver biopsy may result in 
perforated viscera, bleeding and infection. 
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Pathologic features that are common to all forms of cirrhosis 
include hepatic parenchymal necrosis, alteration in parenchymal 
architecture with nodular regeneration and scarring
22
 Specific histological 
patterns seen in some types of cirrhosis are reviewed here.  
Grossly, cirrhosis can be classified as micronodular, macronodular, 
or mixed. 
In ALD the liver is grossly enlarged measuring 1500-2000g but 
with the advent of cirrhosis the liver shrinks. The liver surface is irregular 
and diffusely covered with small regenerative nodules that are less than 3 
mm in diameter. This is described as micronodular cirrhosis 
22
 Mallory 
bodies and diffuse fat accumulation are seen on microscopy, but are not 
specific. The pericentral (centrilobular) 
22
 accumulation of fat can 
progress to complete obliteration of the central vein. When a thin band of 
connective tissue connects portal zones, the pattern is described as 
„central-central‟ pattern. On Trichrome staining this gives a characteristic 
“chicken-wire” appearance. Electron microscopy shows collagenization 
of the space of Disse and Giant mitochondria. 
 
Chronic viral hepatitis causes macronodular cirrhosis, characterized 
grossly by a dense, shrunken liver and large regenerative nodules 
connected by broad bands of connective tissue
22
. Microscopically, 
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irregular bands of connective tissue are prominent and involve three or 
more portal tracts in a single scar. In hepatitis B, HBsAg containing 
“ground glass hepatocyte” may be identified on hematoxylin and eosin 
stain. Bile duct damage and lymphocyte infiltration are prominent in 
cirrhosis caused by hepatitis C. 
 
Cardiac cirrhosis is secondary to chronic congestive heart failure or 
constrictive pericarditis and resembles alcoholic cirrhosis. On gross 
inspection the liver is nodular and on microscopy centrilobular sclerosis 
can be identified
22
 .The hallmark of cardiac cirrhosis is the presence of 
dilated, blood filled hepatic sinusoids
34
.Breakdown of RBCs results in 
hemosiderin deposition and lipid laden macrophages. Fibrous bands 
bridge central areas with relative portal sparing. Cirrhosis caused by 
Budd-Chiari syndrome results from obstruction of the hepatic veins and 
can histologically be similar to cardiac cirrhosis with sinusoidal 
congestion and hepatic necrosis. 
 
Biliary cirrhosis has typical histologic findings that include loss of 
interlobular bile ducts and ductal inflammation.
22, 34
 Extensive portal tract 
damage results in a characteristic “jigsaw” (portal-portal) pattern of 
cirrhosis microscopically. Chronic inflammation around cholangioles and 
terminal plate disruption causes interface hepatitis which was previously 
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known as biliary piecemeal necrosis.
34
 Copper deposition occurs, 
demonstrated with orcein stain. Central vein involvement is rare. 
 
Distinguishing PBC on histology, an increased sinusoidal 
mononuclear infiltrate, portal-based granulomas and hepatocyte necrosis 
are observed. Ductal scarring and periductal fibrosis are classically seen 
in PSC
34 
 
The hallmark histological findings of other causes of cirrhosis are 
summarized in Table 1
15 
 
PROGRESSION TO DECOMPENSATED STATE  
The natural history of cirrhosis is characterized by a prolonged 
asymptomatic compensated phase. The median survival from the time of 
diagnosis of compensated cirrhosis is 10 to 12 years. 60% of such patients 
progress to a decompensated phase in 10 years
35
. The likelihood of 
decompensation in individual patients is difficult to predict due to factors 
including the etiology of disease, amenability to treatment, hepatic 
reserve, other co-morbidities, the development of secondary infections 
and HCC. The ability to eliminate or treat the source of liver injury is of 
prime importance in delaying decompensation and prolonging survival. 
Alcohol abstinence has consistently demonstrated improved survival in 
alcoholic cirrhotics.
36
 Interferon therapy in compensated HCV-related 
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cirrhosis and antiviral treatment for HBV-related cirrhosis retards the 
progression of cirrhosis and decreases the risk of development of HCC.
 37
 
 
The worsening of portal hypertension, hepatic insufficiency and the 
onset of complications heralds the transition from a compensated state to 
decompensation. These complications include jaundice, ascites, variceal 
hemorrhage, and encephalopathy
35,38
. Other complications like 
spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic 
hydrothorax, portopulmonary hypertension, portal vein thrombosis and 
HCC may accelerate clinical deterioration. All these complications have a 
negative impact on the quality of life and prognosis. Cirrhotic patients 
should be vigilantly monitored for the development of these 
complications and targeted therapies should be undertaken to overcome 
these devastating clinical events. In many instances, the onset of hepatic 
decompensation serves as a clinical cue to initiate evaluation for liver 
transplantation in appropriate patients. 
 
The rate of decompensation is 5% to 7% annually.
38
Median survival 
time plummets to approximately 2 years following decompensation.
 35
 
The Baveno IV International Consensus Workshop
39
 agreed upon a 
staging system based on natural history of the disease. The presence or 
absence of ascites, varices and variceal hemorrhage defines each of the 
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stages; the progression through which is accompanied by a dramatic 
increase in morbidity and mortality.  
 Stage 1: the absence of varices and ascites. Probability of death at 1 
year is 1%.  
 Stage 2: The development of nonbleeding varices. Probability of 
death at 1 year is 3.4%.  
 Stage 3: the onset of decompensated phase. Development of ascites 
irrespective of the presence or absence of nonbleeding varices. The 
1-year mortality is 20%.  
 Stage 4: the development of variceal bleeding with or without 
ascites.1-year mortality of 57%. Almost half of these deaths occur 
as a result of initial bleeding episode
38, 39
.  
 
Several prognostic models and scoring systems have been used to 
stratify disease severity and predict survival. The Child-Pugh score 
incorporating five variables (as depicted below) has been demonstrated to 
be a predictor of development complications and survival
40
. 
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The MELD score additionally uses serum creatinine and was 
initially designed to predict the mortality in patients undergoing 
transjugular intrahepatic portosystemic shunt placement.
41
 It is now used 
to prioritize patients awaiting organ allocation and has proved to be a 
predictor of survival. 
 
PORTAL HYPERTENSION: 
Portal hypertension is defined as a portal pressure gradient 
exceeding 5 mm Hg
22
. It is a pathological process characterized by 
increase in portal venous pressure gradient between the inferior vena cava 
and portal vein. 
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ANATOMY, CAUSES AND HEMODYNAMIC PRINCIPLES: 
The portal venous system drains the entire gastrointestinal tract 
except the proximal oesophagus and very distal rectum. It also drains the 
spleen, pancreas, and the gallbladder. Portal veins forms when the 
superior mesenteric vein and splenic vein coalesce behind the neck of the 
pancreas. The portal vein then traverses the gastrohepatic ligament to 
reach the hilum of the liver and divides into right and left portal veins. 
Then further branches out into portal venules which feed into the hepatic 
sinusoids. The sinusoids eventually drain into the hepatic veins, finally 
emptying into the retrohepatic inferior vena cava
42, 43
. 
Portal hypertension occurs from changes in portal resistance along 
with changes in portal blood flow, as defined by Ohm's law
43
:  
        
                            
The mechanism of the rise in portal pressure depends on the cause 
and site of portal hypertension (table 2), cirrhosis being the most common 
cause
22
.  In cirrhosis an increase in resistance to outflow of blood results 
in portal hypertension
22
. This results from a fixed component from 
disruption of hepatic architecture leading to the distortion of hepatic 
vascular pattern and a dynamic component from impaired intrahepatic 
vasodilatation. An intrahepatic decrease in the synthesis of the nitrous 
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oxide (vasodilator) 
44
, along with an increase in the production of the 
endothelin-1(vasoconstrictor) contributes to the dynamic component of 
increase in hepatic vascular resistance
45
. 
Table 2: Causes of portal hypertension
22,43 
Pre sinusoidal: 
Prehepatic- 
Portal vein thrombosis 
Superior mesenteric vein thrombosis 
splenic vein thrombosis or sinistral portal hypertension 
Intrahepatic- 
Primary sclerosing cholangitis  
Primary biliary cirrhosis 
Idiopathic portal hypertension 
 
Sinusoidal: 
Cirrhosis 
Infiltrative disorders (e.g., myeloproliferative and lymphoproliferative 
diseases)  
Vitamin A toxicity 
 
 
Post-sinusoidal: 
Budd-Chiari syndrome 
Veno-occlusive disease 
Congestive heart failure 
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Collaterals exist between the systemic venous system and the portal 
system. However owing to the lower resistance in the portal bed, blood 
flows from the systemic bed into the portal bed. With the development of 
portal hypertension there is a reversal of flow in these collaterals. In an 
attempt to decompress the ever increasing portal pressure, there is 
increase in size of the existing collaterals and development of newer ones 
due to angiogenesis. The locations and vessels involved in collateral 
formation are shown in table 3. Most patients have large collateral flow 
through the short and left gastric veins, hence forming gastro-oesophageal 
varices. Unfortunately these collaterals are insufficient to decompress the 
portal pressure and lead to complications including variceal bleeds and 
encephalopathy. 
Table 3 -- Location and blood vessels of collaterals between the 
portal and systemic venous systems 
Location Portal System Systemic System 
Distal oesophagus and 
proximal stomach 
Short gastric and left gastric 
(coronary) vein 
Azygous vein 
Rectum Inferior mesenteric vein Pudendal vein 
Umbilicus (caput medusa) Left portal vein Umbilical vein 
Retro peritoneum Mesenteric veins Renal vein or 
iliac veins 
 32 
 
Portal pressure is measured by the hepatic vein pressure gradient 
(HVPG). It is the difference between the wedged hepatic venous pressure 
(reflecting the sinusoidal pressure) and free hepatic vein pressure
46
. 
Measurement of the HVPG in combination with pressure measurements 
of right heart, venography and transjugular liver biopsy delineates the site 
i.e., sinusoidal, presinusoidal or postsinusoidal. 
Varices form when HVPG is more than 10 mm Hg and they tend to 
bleed when it exceeds 12 mm Hg 
47
. But this is not applicable in all 
patients. Certain local factors are also involved in increasing the variceal 
wall tension
48
. Frank's modification of Laplace's law defines the wall 
tension as: T = (P varices – P esophageal lumen) × (radius of varix)/wall 
thickness. The varix ruptures when the variceal wall thins out and the 
tolerated wall tension is exceeded, the varix increases in pressure and 
diameter. Large varices at sites of limited soft tissue support especially at 
the gastroesophageal junction are at greater risk of rupture and bleeding. 
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OESOPHAGEAL VARICES: DIAGNOSIS AND CURRENT 
STAGING 
The gastroesophageal area is the main site of varix formation
49
. The 
gastric portions of the varices extend for 2 to 3 cm into the fundus. Along 
the lesser curvature, they drain into the left gastric or coronary vein and 
into the portal vein. Along the greater curvature, they drain through the 
short gastric veins into the splenic vein. Dilation of these veins causes 
gastric varices. The collaterals in the submucosa do not communicate with 
the periesophageal veins in the lower 2-3 cms of the oesophagus and 
hence cannot be easily decompressed. Above this level, the varices can 
extend upwards but easily decompress through the perforating veins. This 
is why oesophageal varices bleed only at the lower end, and is the site 
where various therapies should be targeted. 
 
All patients diagnosed with cirrhosis must be screened for 
Oesophageal Varices. It should be suspected in patients with spider nevi, 
jaundice, caput medusa, splenomegaly, ascites and encephalopathy. 
DIAGNOSIS OF OESOPHAGEAL VARICES  
1. UPPER GASTRO-INTESTINAL SCOPY (UGI SCOPY): 
It is the most common method employed and current guidelines 
recommend that all cirrhotic patients should undergo UGI SCOPY to 
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screen for varices. If no varices are found, a repeat UGI SCOPY should 
be performed in 2 to 3 years and if small varices are seen, UGI SCOPY 
should be repeated in 1 to 2 years or at onset of decompensation, 
whichever is earlier
6
. 
As it enables direct visualization of the varices, it is the gold 
standard for diagnosis of oesophageal varices and helps in decision 
making by assessing the size and the presence of cherry spots and red 
wale signs. Also, it allows for prophylactic or therapeutic variceal band 
ligation in the same sitting. 
 
Techniques adapted in diagnosis of varices on UGI SCOPY-   
i. Examination for varices should be performed during 
withdrawal of the scope. 
ii.  The oesophagus must be maximally inflated, thus flattening 
out any folds masquerading as varices. 
iii. Varices must be described as to their location in the 
oesophagus (lower, middle, or upper) and their size (small 
[<5 mm, Fig. 2] or large [>5 mm, Fig. 3]).  
iv.  Lower oesophageal varices are at maximum risk of bleeding 
and therefore should be graded and described.  
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2. CAPSULE ENDOSCOPY: 
Capsule endoscopy (CE) uses the Pill Cam Eso measuring 26 by 11 
mm. Initial pilot studies demonstrated that this device is well tolerated and 
safe
 50
. A meta-analysis by Lu and colleagues
51
 showed a pooled 
sensitivity and specificity of 85.8% and 80.5% respectively for detection 
of oesophageal varices. Many studies have shown good patient tolerance 
and satisfaction with CE as compared to UGI SCOPY
52
. With lower 
sensitivity and specificity than UGI SCOPY, it is a less effective mode of 
diagnosis, but may be considered in patients unable to tolerate UGI 
SCOPY or unwilling to undergo the procedure. 
 
3. ENDOSONOGRAPHY: 
Endoscopic ultrasound (EUS) examination of the portal vasculature 
is not routinely used for screening for oesophageal varices.  EUS is as 
good as UGI SCOPY in identifying clinically significant oesophageal 
varices
 
but better than UGI SCOPY in identifying gastric varices
53
. The 
EUS has been also used to study predictors for recurrence of varices after 
therapy. The presence and size of para-oesophageal varices were 
associated with recurrent varices. EUS can also be used to predict the risk 
of bleeding by estimating the variceal wall tension when combined with 
endoscopic manometry and to guide therapy. 
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    4. ULTRASONOGRAPHY(USG): 
Ultrasound examination is the most commonly employed technique 
in evaluation of cirrhosis. In combination with Doppler it can identify 
complications of portal hypertension such as ascites and development of 
collaterals. Findings such as splenomegaly, portosystemic collateral blood 
flow and reversal of flow in the portal vein are indicative of portal 
hypertension. The portal vein diameter has been studied as a screening 
parameter for detection of oesophageal varices, wherein a portal vein 
diameter of more than 13 mm correlates with the presence of varices 
(odds ratio 2.92 [95% CI 1.2–6.4])11, 54. It can also demonstrate 
thrombosis in the portal or splenic vein.  
 
5. TRANSIENT ELASTOGRAPHY (TE) 
 It measures liver stiffness by employing pulse echo ultrasound 
readings. Since advanced fibrosis and cirrhosis leads to portal 
hypertension, an association with the degree of liver stiffness on TE with 
the presence of oesophageal varices has been studied. Kazemi F and 
colleagues
55
 found that liver stiffness of less than 19 kPa had a negative 
predictive value of 93% for small oesophageal varices. In patients 
resistant to any invasive procedures, TE appears to be a good screening 
tool. 
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6. COMPUTER TOMOGRAPHY (CT): 
CT can identify the cirrhotic configuration of the liver and signs of 
portal hypertension such as ascites, splenomegaly and collateral vessels. 
(Fig. 6). Helical liver CT had variceal detection rates of 92% for large 
varices and 53% for small varices as compared to UGI 
SCOPY.
56
Multidetector CT scans of the abdomen had a sensitivity and 
specificity of 90% and 50% respectively for diagnosing large oesophageal 
varices
57
. CT also identified a significant number of other pathologies like 
gastric, perioesophageal varices and extra luminal pathologies. Patients 
also showed better compliance with CT. 
 
7. MRI 
MRI with elastography is being studied to determine fibrosis in the 
liver. MRI also provides an excellent view of the vascularity of the liver 
and the flow through the portal and azygous veins. Flow in the azygous 
veins were higher in subjects with portal hypertension than in normal 
controls and peaked at midnight which helps guide the timing of treatment 
with beta blockers
58 
              Gadolinium-enhanced MRI had a sensitivity of 81% in detecting 
oesophageal varices
59
. A significant correlation was seen in the grading of 
varices between endoscopy and MRI.  
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GRADING OF OESOPHAGEAL VARICES: 
Endoscopic grading of oesophageal varices is subjective and there is 
considerable interobserver variability. Three grading systems are well 
known: by Dagradi
60
 (1972); by the Japanese Research Society for Portal 
Hypertension (JRSPH, 1980)
61
; and by the North Italian Endoscopy Club 
for the Study and Treatment of oesophageal varices (NIEC, 1988).
62
 
 Dagradi classifies oesophageal varices into five grades: 
I: 1 to 2 mm in diameter, and straight or sigmoid shaped. 
II: Similar to stage I but visible without occluding blood flow in the vessel. 
III: 3 to 4 mm in diameter and straight or tortuous. 
IV: 4 to 5 mm in diameter, tortuous, often coiled, seen in all quadrants of 
the oesophagus. 
V: Greater than 5 mm in diameter, tightly packed, grape-like, covered by 
thin, wrinkled mucosa, with overlying cherry red spots and 
telangiectasias. 
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 The JRSPH system grades varices based on location, form, color, 
and red color sign: 
 The location of varices may be upper, middle, or lower 
third of the oesophagus. 
  The form is classified as small and straight (F1), enlarged 
and tortuous (F2), or large and coil shaped (F3). 
 The color of the varices is graded as white (Cw) or blue 
(Cb). 
 Also included is the presence of the red color sign (RC) 
that are dilated, small vessels (red wale sign), and 
telangiectasias or cherry-red spots on the surface of the 
varices (Fig. 8). 
 The NIEC index takes into account the following 
 The Child-Pugh class of cirrhosis (A, B, or C) 
 Variceal size (small, medium, or large) 
 Presence of red color signs (absent, mild, moderate, or 
severe). 
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         Of these, oesophageal varices size and red color signs are the most 
important signs. When compared with each other in a study by Rigo G.P 
and colleagues
63
,the JRSPH and NIEC classifications were found to have 
high specificity in predicting variceal bleeding (93.4% and 94.8%, 
respectively) but not sensitive. All the three systems had low positive 
predictive values. None the less, the NIEC and JRSPH classifications are 
commonly used to describe oesophageal varices in investigative and 
clinical settings. 
 
The Baveno I consensus conference recommends that oesophageal 
varices should be classified as small (<5 mm) and large (>5 mm) 
64
. This 
cutoff of 5 mm was confirmed as being optimal to differentiate small from 
large varices. The guideline for primary prophylaxis of oesophageal 
varices differs based on whether varices are small or large. Patients with 
large-size varices, red color signs and Child-Pugh class C have the highest 
risk for bleeding within 1 year. 
 
PROPHYLACTIC TREATMENT OF OESOPHAGEAL VARICES: 
1. Pharmacologic modalities 
Nonselective beta-blocking drugs such as propranolol and nadalol 
are the first line modality for primary prophylaxis. They inhibit the beta-
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adrenergic receptors mediated vasodilatation, allowing unopposed alpha-
adrenergic receptor mediated vasoconstriction in the mesenteric arterioles. 
This effectively reduces portal venous inflow and hence the pressure. 
They also reduce cardiac output hence further decreasing the portal 
inflow. Meta-analysis of various clinical trials shows that the beta-blocker 
therapy decreases the risk of bleeding oesophageal varices by 25% to 15% 
when compared with placebo
65
. The HVPG accurately assess the 
effectiveness of this therapy. A sustained decrease in the HPVG < 12 mm 
Hg is the best predictor of successful treatment
47
 though this approach is 
not routinely and widely applied to clinical practice. Clinically the 
efficacy of beta blockers is monitored by a reduction in the resting heart 
rate of more than 25%. Only 20% to 30% of patients achieve these 
endpoints while 15% to 20% do not tolerate these doses, which may 
require discontinuation. 
Nitroglycerin (short acting) or Isosorbide mononitrates(long-acting)  
are nitrates which cause venodilatation. This causes a decrease in portal 
venous blood flow and decreases the portal pressure. They do not affect 
the intrahepatic resistance. As they failed to demonstrate consistent results 
in various clinical trials, nitrates are not recommended for primary 
prophylaxis anymore.  
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Endothelin receptor antagonist and liver-selective nitrous oxide 
donors that specifically target intrahepatic vascular resistance are 
promising future investigational therapies
66
. 
2. Endoscopic sclerotherapy 
Prophylactic endoscopic sclerotherapy (EST) initially was found to 
significantly reduce the risk of variceal bleed and improve survival. But 
subsequent trials failed to demonstrate this survival benefit. EST may 
actually provoke bleeding that may be difficult to control and may further 
increase mortality
67
. Consequently, EST is not recommended for 
prophylaxis of oesophageal varices
43
. 
3. Endoscopic variceal ligation 
Endoscopic variceal ligation (EVL) significantly decreases the risk 
of first bleeding episode when compared with propranolol 
68
, with a 
relative risk reduction of 40%.Though no survival benefit over 
propronolol was demonstrated. It is also known to be associated with 
fewer complications than EST.  
In summary, EVL and non selective beta blockers are 
recommended first-line modalities for primary prophylaxis of variceal 
hemorrhage. In patients who do not tolerate beta blockers EVL may be 
used.  
 43 
 
MANAGEMENT OF AN ACUTE OESOPHAGEAL VARICES 
BLEED: 
The management of an acute oesophageal varices bleeding includes 
hemodynamic resuscitation, achievement of hemostasis, prevention of 
complications and supportive treatments. The systolic blood pressure 
should be maintained at least at 90 to 100 mm Hg and a hemoglobin level 
around 9 g/dL (hematocrit of 25–30). A rebound increase in portal 
pressure has been identified with overzealous transfusion and which may 
precipitate early rebleeding 
69
. Correction of coagulopathy is by using 
platelets (platelet count <50,000/ml) and Fresh frozen plasma. However 
they can also induce volume overload and lead to 
rebound portal hypertension. Recombinant factor VII use has shown to 
improve hemostasis, but no survival benefit was demonstrated
70
. 
Infections are associated with an elevated risk of rebleeding 
episodes and higher mortality
71
. Spontaneous bacterial peritonitis, 
pneumonia and urinary tract infections are commonly encountered. A 
complete microbiological work-up should be performed. Many clinical 
trials have demonstrated an improvement in bleeding control and patient 
outcomes with empirical institution of therapy with third generation 
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cephalosporins
72
. Therefore this antibiotic therapy should be initiated 
without delay.  
PHARMACOLOGIC THERAPY: 
Vasopressin and its analogs 
           Vasopressin is an endogenous nonapeptide that causes 
vasoconstriction in the splanchnic bed through its action on V1 receptors 
of the arterial smooth muscle. This reduces the portal venous inflow and 
hence the portal pressure. Its toxic effects include bowel necrosis from 
severe vasoconstriction. A semi synthetic analog, Terlipressin, has a lower 
incidence of systemic toxicity. It increases survival in subjects who have 
variceal bleeding
73
. 
Somatostatin and its analogs: 
Somatostatin has a half-life of 1 to 3 minutes in circulation. It 
inhibits the release of glucagon, thereby decreasing portal pressure and 
collateral blood flow
74
.  
Octreotide has a longer half-life of 80 to 120 minutes. Although its 
effects on decreasing portal pressure is not prolonged. Early institution of 
vapreotide may be associated with better bleeding control but without a 
significant decrease in mortality
75
. 
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ENDOSCOPIC TREATMENTS: 
Endoscopic sclerotherapy 
EST involves the injection of a sclerosant into or adjacent to a 
varix. This technique has been supplanted by EVL. Complications of the 
procedure include ulcers and ulcer-related bleeding, perforation and 
strictures. Current data does not support emergency EST as first-line 
treatment in acute bleeding oesophageal varices
76
. 
Endoscopic variceal ligation 
EVL is the preferred modality for arrest of acute oesophageal 
varices bleed and for preventing rebleeds
22
. Varices at the GE junction are 
banded first, and then more proximal ones are banded in a spiral manner 
at 2 cm intervals. Varices in the middle or proximal oesophagus are 
associated with lower risk of bleeding and need not be banded. It requires 
fewer sessions to achieve obliteration of varices. 
In summary, in control of active esophageal variceal hemorrhage 
the first line treatment includes a combination of pharmacologic 
intervention (i.e., octerotide) and EVL. 80% to 90% of patients achieve 
good hemostasis with first-line therapy; the remaining either fail to 
achieve hemostasis or have early rebleeding
77
. 
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Bleeding that occurs more than 48 hours after the initial admission 
for hemorrhage and is separated by at least a 24-hour bleed-free interval is 
considered as rebleeding
43
. Factors associated with failure to control 
active bleeding and early rebleeding are summarized in table 4.  
Table 4: Risk factors for re-bleeding or continued bleeding
43 
Failure to control acute hemorrhage 
Spurting varices, infection ,high HVPG, high Child-Pugh score, Portal 
vein thrombosis 
Factors associated with early rebleeding 
Severe initial bleeding, infection, over enthusiastic volume resuscitation 
High HVPG, renal failure, Complications of endoscopic therapy 
Factors associated with late rebleeding 
High Child-Pugh score, continued alcohol use, Large varices, 
Hepatocellular carcinoma 
In patients with uncontrolled active bleeding, definitive salvage 
therapy should be initiated at the earliest. Balloon tamponade produces 
effective hemostasis in 80% to 90% cases
78
. Airway should be secured to 
prevent aspiration. It is associated with a high risk of rebleeding on 
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deflation of the balloon and with pressure necrosis if kept inflated for > 48 
hours. Therefore it is used as a bridging treatment until definitive 
treatment can be started. 
 EVL can be attempted a second time for early rebleeding. The 
salvage treatment in such patients is portal decompression surgeries, with 
transjugular intrahepatic portosystemic shunts (TIPS) being the procedure 
of choice. 
Transjugular intrahepatic portosystemic shunts (TIPS) 
TIPS decreases the elevated portal pressure by creating a 
communication between the hepatic vein and an intrahepatic branch of the 
portal vein. It produces effective hemostasis in over 90% patients
79
. The 
prognosis becomes dismal with the occurrence of complications from 
bleeding such as aspiration pneumonia or multiorgan failure. Patients with 
aspiration pneumonia have been demonstrated to have a 10% survival at 
30 days
80
. The MELD score (discussed earlier) is the best predictor of 
mortality following TIPS. 
Contraindications to TIPS are portal vein thrombosis with 
cavernoma formation, severe hepatic failure, severe congestive cardiac 
failure, severe pulmonary hypertension and polycystic liver disease. 
Surgical decompression using portosystemic shunts is also a salvage 
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modality, but its use has declined due to the increasing availability of 
TIPS and a higher associated morbidity. 
Secondary prophylaxis 
Following an index bleed, 70% patients have a recurrent variceal 
hemorrhage within 1 year
81
, and have 70% 1-year mortality. The risk of 
rebleeding is highest in the first 6 weeks, with over 50% of these 
occurring within 3 to 4 days. Risk factors include severe initial bleed, Age 
>60 years, large oesophageal varices, severe liver disease, renal failure, 
continued alcohol intake and the presence of a hepatoma
82
. 
The first-line therapy for secondary prophylaxis of oesophageal 
varices hemorrhage is EVL and beta-blockers. A meta-analysis 
demonstrated that TIPS is superior to endoscopic treatment in the 
prevention of rebleeding (19% versus 47%)
83
, but this advantage is offset 
by its higher morbidity owing to the development of hepatic failure and 
encephalopathy (34% versus 19%), failure to prolong survival and its lack 
of a cost benefit
84
. Hence TIPS is used as a salvage therapy in patients 
with recurrent hemorrhage despite adequate primary treatment.  
In summary, modalities recommended for secondary prophylaxis of 
oesophageal varices hemorrhage are as follows
43
: 
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1. Eradication of oesophageal varices by EVL (every 1-2 weeks until 
varices are obliterated) with concomitant use of nonselective beta-
blockers (propranolol or nadolol) 
2. Nonselective beta-blocker therapy can be used alone if EVL is 
unavailable or contraindicated 
3. TIPS is considered if endoscopic and pharmacologic therapies fail. 
(Recurrence of bleeding despite at least two sessions of endoscopic 
treatment done not more than 2 weeks apart). 
Prevention of recurrent hemorrhage, preservation of liver function, 
maintenance of renal function, prevention of ascites and abstinence from 
alcohol are known to prolong survival. Orthotopic liver transplant is the 
only modality of treatment that is able to achieve most of these objectives 
and hence prolongs long-term survival. Always consider liver 
transplantation if the patient is Child-Pugh B or C. 
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METHODOLOGY 
STUDY DESIGN  
This is a non randomized, single center prospective study which 
analyses the correlation between clinical features, biochemical data and 
ultrasonographic findings with the presence of oesophageal varices in 
patients with cirrhosis. The study aims at identifying PSR as a non invasive 
tool in diagnosis of oesophageal varices in patients with advanced liver 
disease and to assess its predictive value. 
 
STUDY   CENTRE 
This   study   was   carried  out  at   The  Department  Of  Internal  
Medicine and The Department of Medical Gastroenterology ,  Thanjavur 
Medical  College  Hospital ,  Thanjavur,  Tamil Nadu,  India.   All the 
patients admitted during the study period with features of cirrhosis and 
portal hypertension that was newly diagnosed underwent clinical 
examination, blood tests, ultrasound abdomen and UGI endoscopy.  The 
findings   were   recorded   in   the proforma annexed herein.  The data 
hence obtained was recorded in the master chart annexed herein. 
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STUDY   PERIOD 
Newly diagnosed cases of cirrhosis with portal hypertension admitted 
during the period October 2011 to October 2012 were included   in   this    
study. A total number of 60 cases, 41 males and 19 females were studied. 
INCLUSION CRITERION: 
1. Patients newly diagnosed of cirrhosis and portal hypertension, 
admitted between October 2011 and October 2012. 
2. Patients over the age of 13 yrs. 
3. H/o atleast 6 months of abstinence from alcohol  
EXCLUSION CRITERION: 
1. Patients with unstable vitals at admission.  
2. Active gastrointestinal bleeding at admission(bleeders) 
3. H/0 treatment for oesophageal varices- band ligation, sclerosis 
4. H/o Transjugular intrahepatic portosystemic shunt (TIPS), or any 
surgery for portal hypertension. 
5. H/o taking drugs for primary prophylaxis of variceal bleeding.  
6. H/0 active alcohol abuse 
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STUDY CHARACTERISTICS: 
Age, gender and the etiological diagnosis were recorded for all the 
patients. All patients were subjected to biochemical analysis including liver 
function tests, serum albumin estimation, PT-INR (prothrombin time-
international normalized ratio). Platelet counts were checked using cell 
counters and then by manual method. All patients underwent abdominal 
ultrasonographic examination for measurement of diameter of spleen (in 
mms). Spleen diameter was determined based on the longest dimension of 
spleen on ultrasound. 
Ultrasonographic findings were recorded by an experienced 
sonologist. 
All the patients underwent UGI endoscopy to determine the presence 
and size of oesophageal varices. The criteria proposed at the Baveno I 
Consensus Conference were used to further classify the varices into small 
and large. Varices that flatten with insufflations of saline or minimally 
protrude into the oesophageal lumen were deemed small varices and those 
with presence of confluence (varices protruding into the lumen and touch 
each other), or that obscure at least 50% of the oesophageal lumen was 
called large varices. All the endoscopies were carried out by an experienced 
gastroenterologist in a single endoscopy unit. 
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 The PSR was calculated for all the patient using the serum Platelet 
Count (in N/mm3) and Spleen Diameter (in millimeters).  
All the patients were further stratified according to Child - Pugh‟s 
criteria under classes A, B and C. The data hence obtained were all recorded 
in the master chart annexed herein. 
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RESULTS AND OBSERVATION    
FREQUENCY TABLES 
                  In this study, all patients with newly diagnosed cirrhosis were 
stratified into three age groups as depicted below. The highest number of 
patients was between the ages 26- 50 years, which comprised of 66.7% of 
the study population. This was followed by 21.7% of patients over 51 yrs 
and 11.7% below 25yrs 
                          TABLE 5: AGE DISTRIBUTION 
Sl.no Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
1 Below 25yrs 7 11.7 
2 26 to 50yrs 40 66.7 
3 51yrs & above 13 21.7 
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                                   CHART 1:  
PIE CHART SHOWING AGE DISTRIBUTION 
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TABLE 6: GENDER DISTRIBUTION 
Sl.no Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
1 Male 41 68.3 
2 Female 19 31.7 
 
Out of 60 patients included in the study group, 41 were male and 19 
were female. Male to female ratio was 2.1:1. This shows a clear male 
preponderance. 
CHART 2:  
PIE CHART SHOWING GENDER DISTRIBUTION 
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CHART 3: ETIOLOGY 
 
                    
               As depicted in the above chart, alcoholism was found be the most 
common etiology of cirrhosis (50%) in this study population, followed by 
viral hepatitis (hepatitis B and hepatitis C) and cryptogenic cirrhosis. Other 
causes of cirrhosis accounted for less than 10% cases. 
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SPLEENOMEGALY: 
On clinical examination, splenomegaly was recorded as absent, mild 
and moderate spleen. Massive splenomegaly was not seen in this study 
hence excluded. No spleen enlargement was found in 17 patients (28.3%), 
mild splenomegaly in 23 patients (38.3%) and moderate splenomegaly in 20 
patients (33.3%).  
CHART 4: PIE CHART SHOWING PREVALENCE OF 
SPLEENOMEGALY 
SPLEEN SIZE
28%
39%
33% NO SPENOMEGALY
MILD SPLENOMEGALY
MODERATE
SPLENOMEGALY
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ASCITES AND ICTERUS: 
Also, presence or absence of ascites and icterus were observed during 
clinical examination. It was found that 38 out of 60 patients had 
ascites(63.3%) while 35 out of 60 had icterus(58.3%). 
CHART 5: BAR DIAGRAM SHOWING PREVALENCE OF 
ASCITES AND ICTERUS 
63.30%
36.70%
58.30%
41.70%
ASCITES ICTERUS
PRESENT ABSENT
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OTHERS:  
Clinical parameters associated with complications of varices such as 
encephalopathy and spontaneous bacterial peritonitis were also noted. These 
dramatic events were present in only 5 patients and absent in the 
majority(88.3%). 
Table 7: Prevalence Of Complications Of Cirrhosis 
Sl.no Particulars 
No.of respondents 
(n=60) 
Percentage 
(100%) 
1 Nil 53 88.3 
2 Encephalopathy 4 6.7 
3 SBP 1 1.7 
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BIOCHEMICAL PARAMETERS- 
TOTAL BILIRUBIN 
CHART 6: DISTRIBUTION OF TOTAL BILIRUBIN IN THE STUDY 
POPULATION 
45%
21.60%
33.33%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
TOTAL BILIRUBIN
<2 mgs 2-3mgs >3 mgs
 
Total bilirubin was estimated in all patients, 27 out of 60(45%) had a 
level of <2 mg/dl, 13 patients had levels between 2-3mg/dl (21.6%) and the 
rest i.e. 20 patients(33.3%) had levels above 3 mg/dl. The mean total 
bilirubin levels were estimated to be 3.3+/- 3.07 mg/dl. 
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SERUM ALBUMIN: 
CHART 7: DISTRIBUTION OF SERUM ALBUMIN IN THE STUDY 
POPULATION 
SERUM ALBUMIN
30% 40%30%
0%
5%
10%
15%
20%
25%
30%
35%
40%
<2.8g/dl 2.8-3.5 g/dl >3.5g/dl
 
Serum albumin levels were <2.8g/dl in 30%, between 2.8-3.5 g/dl in 
30% and >3.5% g/dl in 40%. 
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PT-INR: 
PT-INR was calculated for all patients included in the study. An 
elevated PT-INR >2.3 was found in majority of patients (48.3%). 30% had 
values in between 1.7-2.3 and 21.6% had a PT-INR of less than 1.7.  
CHART 8: DISTRIBUTION OF PT-INR IN THE STUDY 
POPULATION 
PT-INR
22%
30%
48%
<1.7 1.7-2.3 >2.3
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PLATELET COUNTS: 
Platelet counts were obtained by automated cell counters used in our 
central lab and were cross checked by manual examination. They are 
expressed as counts/mm
3
. It was found that while 33.3% had platelet count 
>1.2 lakhs/mm
3
, only16.6% had counts <80 000/mm
3
. But 37.5% patients 
with large varices had counts <80 000/mm
3 
while only around 12% had 
counts over 1.2 lakhs/mm
3
. This was statistically significant as depicted in 
table 10. 
CHART 9: DISTRIBUTION OF PLATELET COUNT IN THE  
STUDY POPULATION 
26.60%
23.30%
33.30%
16.60%
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
PLATELET COUNT
<80 000/mm3 80000-1 lakh
1 lakh-1.2 lakh >1.2 lakhs
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 UGI SCOPY: 
CHART 10: BAR DIAGRAM SHOWING DISTRIBUTION OF 
VARICES IN THE POPULATION 
 
UGI scopy using video endoscope demonstrated the presence of large 
varices in 24 study patients (40%), absent varices in 19(31.7%) and small 
varices in 17(28.3%). 
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CHILD-PUGH’S SCORE: 
Chart 11: pie chart showing stratification of patients according to 
Child-Pugh‟s scoring: 
 
Child Pugh score was calculated using the five parameters- ascites, 
encephalopathy, total bilirubin, serum albumin and PT-INR. Patients were 
classified into class A, B and C respectively. 29 out of 60 patients fell in the 
class C, accounting for 48.3%, class B had 28.3% and class A constituted 
23.3% of all patients. Hence the largest population was of patients with 
decompensated disease. 
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PLATELET COUNT / SPLEEN DIAMETER RATIO 
Based on data collected, a platelet count/spleen diameter cut off of 
909 was applied in this study.  41 patients out of 60 had a ratio <909(70%) 
and the other 19 had a ratio of >909(30%) 
CHART 12:  
DISTRIBUTION OF PATIENTS WITH PSR CUTOFF OF 909 
70%
30%
0
10
20
30
40
50
60
70
<909 >909
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TABLE 8: DESCRIPTIVE STATISTICS: 
Item n Min. Max. Mean S.D. 
Age 60 16 65 40.48 12.043 
Total bilirubin 60 .80 15.20 3.3367 3.07455 
AST 60 25 560 199.07 130.968 
ALT 60 22 555 158.73 119.248 
Serum albumin 60 1.00 5.50 3.3233 1.06044 
PT-INR 60 1.00 4.00 2.3680 .77854 
Splenomegaly(USG) 60 100 180 139.70 15.938 
PSR 60 375.00 1500.00 842.3748 260.39289 
 
From statistical analysis of data obtained from the study, the average 
age of a patient with cirrhosis in this group was 40.48 with a SD (standard 
deviation) of 12.04. The mean spleen size on ultrasound was 139.7mms 
(123-157). The mean PSR was 842.37 with a SD of 260.39. 
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Table 9: Oneway ANOVA difference between UGI Scopy of the  
respondents and their Platelet Count/Splenic Diameter 
Sl.no 
 
Platelet 
Count/Splenic 
Diameter 
Mean S.D SS Df MS 
Statistical 
inference 
1 
Between 
Groups 
  2938461.468 2 1469230.734 
F=78.857 
.000<0.05 
Significant 
 
No varices 
(n=19) 
1158.66 136.304    
 Small (n=17) 769.35 107.954    
 Large (n=24) 643.7108 153.380    
2 Within Groups   1062001.547 57 18631.606 
Statistical test: Oneway ANOVA ‘f’ test was used the above table 
The above table inferred that there is a significant difference between 
UGI Scopy of the respondents(between and within groups) and their PSR. 
Hence, the calculated value less than table value (.000<0.05). 
                Karl Pearson coefficient correlation test was used to compare PSR 
with other non invasive parameters described in the diagnosis of varices. It 
was found there was no significant correlation between PSR and total 
bilirubin, SGOT and SGPT (p>0.05).  
But a significant relationship was found between PSR with presence 
of ascites, low platelet counts, spleen diameter on ultrasonography, PT-INR 
and child Pugh‟s scores (p<0.05). 
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Table 10: Association between Age, Sex, Etiology, Splenomegaly, Ascites, 
Icterus, Others, Platelet count, Child's score of the respondents and their 
UGI Scopy 
Variables 
UGI Scopy 
Statistical 
inference 
No variation Small Large 
(n=19) (100%) (n=17) (100%) (n=24) (100%) 
Age        
Below 25yrs 4 21.1% 2 11.8% 1 4.2% X
2
=3.109 
Df=4 
.540>0.05 
Not Significant 
26 to 50yrs 11 57.9% 11 64.7% 18 75.0% 
51yrs & above 4 21.1% 4 23.5% 5 20.8% 
Sex        
Male 12 63.2% 12 70.6% 17 70.8% X
2
=.344 
Df=2 
.842>0.05 
Not Significant 
Female 7 36.8% 5 29.4% 7 29.2% 
Etiology        
Alcoholic 10 52.6% 7 41.2% 13 54.2% 
X
2
=11.202 
Df=10 
.342>0.05 
Not Significant 
Alcohol + 0 .0% 3 17.6% 3 12.5% 
Viral Hepatitis 2 10.5% 4 23.5% 5 20.8% 
Wilson's 2 10.5% 1 5.9% 1 4.2% 
Cryptogenic 5 26.3% 1 5.9% 1 4.2% 
Autoimmune 0 .0% 1 5.9% 1 4.2% 
Splenomegaly        
No 11 57.9% 4 23.5% 2 8.3% X
2
=16.123 
Df=4 
.003<0.05 
Significant 
Mild 6 31.6% 8 47.1% 9 37.5% 
Moderate 2 10.5% 5 29.4% 13 54.2% 
Ascites        
No 12 63.2% 3 17.6% 7 29.2% 
X
2
=8.971 
Df=2 
.011<0.05 
Significant 
Yes 7 36.8% 14 82.4% 17 70.8% 
Icterus        
No 9 47.4% 7 41.2% 9 37.5% 
X
2
=.427 
Df=2 
.808>0.05 
Not Significant 
Yes 10 52.6% 10 58.8% 15 62.5% 
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Others        
Nil 19 100.0% 15 88.2% 19 79.2% X
2
=8.558 
Df=6 
.200>0.05 
Not 
Significant 
Encephalopathy 0 .0% 1 5.9% 3 12.5% 
SBP 0 .0% 1 5.9% 0 .0% 
Platelet count        
Below 80000 0 .0% 1 5.9% 9 37.5% X
2
=38.223 
Df=6 
.000<0.05 
Significant 
80001 to 1lk 2 10.5% 9 52.9% 7 29.2% 
1lk to 1.2lk 1 5.3% 5 29.4% 5 20.8% 
More than 1.2lk 16 84.2% 2 11.8% 3 12.5% 
Child's score        
A 13 68.4% 1 5.9% 0 .0% X
2
=39.501 
Df=4 
.000<0.05 
Significant 
B 6 31.6% 6 35.3% 5 20.8% 
C 0 .0% 10 58.8% 19 79.2% 
PSR        
Below 909 0 0 15 88.2% 24 100.0% X
2
=55.489 
Df=2 
.000<0.05 
Significant 
Above 909 19 100% 2 11.764% 0 .0% 
Total Bilirubin        
< 2 10 52.6% 7 41.2% 10 41.7% X
2
=4.839 
Df=4 
.304>0.05 
Not 
Significant 
2 to 3 6 31.6% 2 11.8% 5 20.8% 
> 3 3 15.8% 8 47.1% 9 37.5% 
Serum 
Albumin 
       
< 2.8 0 .0% 7 41.2% 12 50.0% X
2
=35.821 
Df=4 
.000<0.05 
Significant 
2.8 to 3.5 1 5.3% 8 47.1% 8 33.3% 
> 3.5 18 94.7% 2 11.8% 4 16.7% 
PT-INR        
< 1.7 11 57.9% 1 5.9% 1 4.2% X
2
=27.946 
Df=4 
.000<0.05 
Significant 
1.7 to 2.3 7 36.8% 6 35.3% 6 25.0% 
> 2.3 1 5.3% 10 58.8% 17 70.8% 
Statistical test: Chi-square test was used the above table 
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The Chi square test was used to study the association of various 
variables with the presence of oesphageal varices on UGI scopy and the 
results so obtained are documented in the above table. The following 
inferences were drawn: there was no significant association between Age, 
Sex, Etiology, Icterus, total bilirubin levels of the patients and their UGI 
Scopy. A significant association was found between Splenomegaly, Ascites, 
Platelet count, serum albumin, PT-INR, Child Pugh‟s score and Platelet 
Count/Spleen diameter of the respondents and their UGI SCOPY. Hence, 
the calculated value less than table value (.P<0.05). This demonstrates that 
PSR can be used in par with the other well known parameters in aiding non 
invasive diagnosis of OVs. 
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CHART 13 
 BAR DIAGRAM DEPICTING ASSOCIATION OF VARICES WITH 
CHILD-PUGH’S SCORE: 
68.40%
31.60%
0
5.90%
35.30%
58.80%
0
20.80%
79.20%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
child's A child's B child's C
no varices small varices large varices
 
The above chart depicts the association of grades of varices as 
observed by UGI scopy with the Child-Pugh‟s class among the study 
population. It shows that 79.2% patients with large varices belonged to class 
C while 20.8% belonged to class B. patients in class A did not have large 
varices. While 68.4% of patients in the no-varices group belonged to class 
A, 31.6% belonged to class B and none were found in class C. This suggests 
that the prevalence of oesophageal varices increases with higher Child-
Pugh‟s class, although a clear cut off is difficult to obtain.  
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PSR vs. UGI scopy: 
CHART 14: BAR DIAGRAM SHOWS THE RELATIONSHIP BETWEEN 
PSR AND VARICES 
0
100%
88.20%
11.76%
100%
0
0
0.2
0.4
0.6
0.8
1
1.2
below 909 above 909
no varices small varices large varices
 
When the association of PSR with grades of varices as diagnosed and 
graded by UGI scopy was studied, it was found that all patients with large 
varices had a PSR<909 and all patients with no varices had PSR>909. 
Interestingly, 15 out of 17 patients with small varices had a 
PSR<909(88.2%) while the other 2 had a ratio of >909(11.8%). This shows 
that while a PSR cutoff of 909 accurately predicted the absence of varices 
and large varices, in prediction of small varices it was less accurate.   
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SENSITIVITY AND SPECIFICITY 
TABLE 11: SENSITIVITY AND SPECIFICITY OF PSR AS A 
DIAGNOSTIC TOOL 
 
Estimated 
Value 
95% Confidence Interval 
Lower Limit Upper Limit 
Prevalence 0.7 0.566268 0.807996 
Sensitivity 0.952381 0.82576 0.991709 
Specificity 0.888889 0.639269 0.980517 
 
Upon consolidation of all the obtained data, PSR showed a sensitivity 
of 95.2% and specificity of 88.8%. Prevalence adjusted positive predictive 
value of the test was found to be 95% and negative predictive value of 89%.  
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                                             DISCUSSION 
In this study conducted during a 1 year period, 60 newly diagnosed 
cases of liver cirrhosis were included. Patients with unstable vitals at 
admission, history of variceal bleeds or treatment (medical or surgical) were 
excluded from the study. 
Out of these 60 patients, 41(68.3%) were males and 19(31.7%) were 
females. A male predominance is probably because of increased incidence 
of alcohol abuse and alcohol related liver disease in this population. 
The highest number of patients was found to be between ages 25-50 
yrs (66.7%). While ages above 51 yrs constituted 21.7%, and below 25 yrs 
constituted of 11.7% of the study population. The mean age was found to be 
40.48 yrs. 
No age or sex difference was observed between patients with 
oesophageal varices (small and large) and group with no oesophageal 
varices, which is comparable with results obtained by E Giannini et al.
1
  
Alcoholic cirrhosis accounted for highest number of cases; 30 out of 
60 patients‟ i.e 50% of the study group. Also coexisting viral hepatitis was 
identified in 6 patients. Both Hepatitis B and C are well known to accelerate 
the progression of liver disease and precipitate decompensation in alcoholic 
cirrhosis. Evidence of viral hepatitis was found in 18.3% patients, forming 
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the second largest group with cirrhosis. Wilson‟s disease diagnosed by 
serum ceruloplasmin levels, KF rings and urinary copper excretion tests was 
found in 4(6.7%) patients. It is noteworthy that all these patients were <21 
yrs of age, implicating that Wilson‟s disease is a cause for early onset 
hepatocellular degeneration. 2 cases of autoimmune disease (3.3%) related 
cirrhosis were encountered. 7 cases had no identifiable etiology and were 
classified as cryptogenic (11.7%). This is comparable with etiological 
distribution shown in other studies. Chang M H and colleagues
85
 found 
that in a study group of 736 patients in 42.4% of liver cirrhosis was due to 
chronic alcoholism, closely followed by viral hepatitis (41.2%). Though 
there is a predominance of alcohol related cirrhosis in our study as well, a 
difference in incidence of viral hepatitis between the two studies maybe due 
to the larger study population in the latter study.  
On clinical examination, important markers of portal hypertension 
and decompensated liver disease were concentrated upon. These were 
splenomegaly, ascites and icterus. As in this population spider naevi are 
difficult to discern they were not included in the study despite their 
association with portal hypertension as demonstrated in other studies.  
17 patients in the study group had no palpable spleen on examination, 
constituting 28.3% of the study population. Majority of the patients had 
mild splenomegaly; 23 out of 60(38.3%). While moderate spleen was seen 
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in 33.3%.  Massive splenomegaly (spleen palpable beyond the umbilicus) 
was not recorded in this study. 54.2% patients with large varices had 
moderate splenomegaly while only 8.3% has no splenomegaly. This 
suggests a strong correlation between spleen size and presence of 
oesophageal varices (p<0.005). Association of splenomegaly with presence 
of oesophageal varices has been well demonstrated by studies like 
Thomopoulos et al
9 
and Chang M H and colleagues
85
.
 
Icterus observed in 35 out 60 patients (58.3%) though the correlation 
between oesophageal varices and presence of icterus was found to be 
insignificant statistically in our study. While 62.5% patients with large 
varices had icterus, 52.6% with no oesophageal varices also had icterus. 
However, Thomopoulos et al
9
 demonstrated serum bilirubin (p = 0.01) as 
one of the variables associated with presence of varices on univariate 
analysis. But they failed to show any significance between the two on 
multivariate analysis.  
Ascites was recorded in 68.3% of the study population. Over 70.8% 
cases with large varices had ascites, while 63.2% patients with absent 
varices had no ascites. The relationship between presence of varices and 
ascites has been found to be statistically significant in our study. Ng FH et 
al
10
 concluded in their study that endoscopic screening for varices were not 
necessary until ascites or thrombocytopenia occurred. Chang MH et al
85
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concluded in their study that patients who have at least two among ascites, 
splenomegaly, and alcoholism would have an increased risk of having large 
esophageal varices . This was also supported by Thomopoulos et al
9
. 
It is noteworthy that a few patients also had advanced complications 
of portal hypertension such as spontaneous bacterial peritonitis(SBP) and 
hepatic encephalopathy. Although no significant correlation between these 
and presence of oesophageal varices was found in our study. However, in 
study by Ng FH et al
10
, patients with hepatic encephalopathy were found to 
be significantly associated with presence of varices.  
Platelet counts have been independently associated with oesophageal 
varices in patients with chronic liver disease and this has been demonstrated 
by a multitude of studies.
1, 7,9,10,54
.Reduced platelet counts in liver disease 
may depend on  factors other than portal hypertension, such as decreased 
thrombopoietin production, reduced mean platelet survival or myelotoxic 
effects of alcohol or hepatitis viruses. And hence, though there is a 
significant association it has low specificity.   
Pilette C et al
7
 concluded in their study that at a diagnostic threshold 
of 160 G/L counts, a sensitivity of 80% and a specificity of 58% was 
obtained. Platelet count ≥260 G/I had a negative predictive value ≥91%. 
Zaman A and colleagues
86
 concluded that a platelet count of <88,000 was 
the only parameter identified by univariate/multivariate analysis (p < 0.05) 
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as associated with the presence of large esophageal varices (odds ratio 5.5; 
95% confidence interval 1.8-20.6) or gastric varices (odds ratio 5; 95% 
confidence interval 1.4-23). Platelet count < 90,000/ μl was found to be 
significantly associated with large varices as demonostrated by Jijo V 
Cherian and colleagues
54
 (OR 2.7; 95% CI, 1.4 – 5.2).  
 A platelet count of <80 000 was seen in only 16.7% and was 
associated with large varices in 37.5% which was significant. On the other 
hand only 12.5% of patients with large varices had a count of above 1.2 
lakhs(35%), while 84.2% had no varices. This finding correlates with other 
studies wherein thrombocytopenia has shown to be associated with varices, 
but a definitive cutoff level is difficult to obtain. 
Patients with large varices had a mean total bilirubin level of 
3.6md/dl, while those with no varices had mean total bilirubin of 2.77. 
There was no significant correlation between the two parameters in this 
study. Although some studies have demonstrated an association
9 
There was no significant correlation between AST and ALT with the 
presence of varices, and this is in accordance with studies by Giannini et 
al
1 
On the other hand parameters like serum albumin and PT-INR 
showed significant associations (p<0.05). Patients with large varices had 
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lower mean serum albumin levels (2.7g/dl) and elevated PT-INR(2.8) as 
demonstrated by Bressler B, Pinto R, El-Ashry D, Heathcote EJ
12
 in their 
study. 
All patients in this study were stratified into Child Pugh‟s class, 
which is also an independent non invasive predictor of oesophageal varices 
in cirrhotics. Majority of the patients, 29 out of 60 fell in class C(48.3%), 
followed by class B(28.3%) and class A(23.3%). The correlation of Child‟s 
scoring and presence of oesophageal varices was found significant in this 
study. Patients with higher Child-Pugh‟s class were found to have large 
varices. None of the patients with large varices belonged to class A while 
79.2% of the cases fell in class C. In a study conducted by Jijo V Cherian 
and colleagues
54
, Child-Pugh class B/C were found to be associated with 
higher grades of varices, which is comparable with our study. 
On UGI scopy, 31.7% patients had no varices and 68.3% showed the 
presence of varices (28.3% -small varices, 40%-large varices). 
Platelet count/spleen diameter was calculated for all patients. 42 
patients had a ratio of <909(70%), and 18 had a ratio of >909(30%). Platelet 
count was found to be significantly associated with clinical parameters like 
ascites and splenomegaly, laboratory parameters like serum albumin and 
PT-INR and radiologically with spleen diameter. But no association was 
found with total bilirubin and the liver enzymes. 
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Significant association was found between presence of varices and 
the platelet count/spleen diameter. Studies by Giannini et al
1
and Baig WW 
and colleagues
13
 also demonstrated that PSR has high accuracy in 
predicting varices non invasively. However, in the study by Baig WW a 
PSR cut off of 1014 was employed and found to have a positive predictive 
value of 95.4% and negative predictive value of 95.1%
13
.  
A platelet count-spleen diameter ratio of ≤ 666 was significantly 
associated with the presence of oesophageal varices in a predominant 
alcohol related cirrhosis subset when studied by Jijo V Cherian and 
colleagues
54
. This ratio was found insignificant on multivariate analysis. 
In this study, all patients with large varices had a ratio <909 and all 
patients with no varices had a ratio>909. However, 11.8% patients with 
small varices had a PSR >909. This denotes that while PSR at a cut off of 
909 accurately predicts absence of varices or large varices, small varices 
were missed in 2 cases.  
The sensitivity and specificity of this test in non invasively predicting 
oesophageal varices is 95.2% and 88.9% respectively, which is comparable 
with the results of the meta-analysis by Ying L et al
14
. The prevalence 
adjusted positive predictive value was 95% and the negative predictive 
value was 89%. 
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CONCLUSION 
1. Platelet count/spleen diameter is valuable tool in non invasive 
prediction of oesophageal varices in patients with cirrhosis. 
2. Platelet count/spleen diameter was independently associated with 
presence of oesophageal varices on UGI scopy.(p<0.05) 
3. Platelet count/spleen diameter was also found to strongly correlate 
with other non invasive diagnostic tools like ascites, splenomegaly, 
platelet count, serum albumin, PT-INR and Child Pugh‟s score. 
4. It had a sensitivity of 95.2% and specificity of 88.9% in predicting 
oesophageal varices in patients with cirrhosis when a cut off 909 was 
applied. 
5. Platelet count/spleen diameter had a prevalence adjusted positive 
predictive value of 95% and prevalence adjusted negative predictive 
value of 89%. 
6. To some extent, this parameter also helps predict large and small 
varices. The ratio being smaller in patients with larger varices. 
Although further studies are required for validation of this and for 
detecting valid cut off ratios.   
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7. The use of platelet count/spleen diameter ratio would avoid 
unnecessary endoscopy in patients with cirrhosis without a significant 
risk of missing oesophageal varices. 
8. Platelet count/spleen diameter ratio can be calculated easily, is 
reproducible and less cumbersome than UGI scopy. 
9. In a rural setup where UGI scopy may not be possible, platelet 
count/spleen diameter may be of help to the physicians in helping 
initiate appropriate primary pharmacological prophylaxis in these 
patients.  
10. In urban settings where endoscopic workload is high, this non 
invasive predictor can help to initiate drug therapy while waiting for 
the endoscopy procedure. 
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1 Basheer ahmed 53 male 1379696 alcoholic 3cms + + 5.4 210 120 2 2.8 80 000 150 533 large C
2 vijay kumar 35 male 1379681 alcoholic no + + 6 145 120 3.4 2.4 80 000 120 666 small C
3 vasugi 33 female 1366121 cryptogenic 3 cms no no 1.4 124 150 4.5 1.6 1.5 lakhs 140 1071.4 NO VARICES A
4 prabhakaran 50 male 1386978 alcoholic no no + 2.8 145 50 4.5 1.4 1.4 lakhs 120 1250 NO VARICES A
5 valiyapathy 55 female 1388177 hepatitis B 5 cms + no 0.9 70 56 1.8 2.8 90 000 160 562.5 small C
6 arul doss 55 male 1388190 alcoholic 2 cms + no 1.1 160 100 3 2.8 1.3 lakhs 150 866.6 large B
7 muthaiyya 42 male 1388210 alcoholic, 
hepatitis B
4cms + no 1.1 145 110 1.4 3.08 1.1 lakhs 150 733.33 large C
8 kaliyaperumal 48 male 1388612 alcoholic 4cms + + 2.8 245 145 3 3 80 000 154 519.4 large C
9 muthalakshmi 50 female 1320576 cryptogenic no + no 0.8 25 22 4 2.8 1 lakh 130 769 large B
10 kannan 32 male 1312517 alcoholic, 
hepatitis B
2 cms + + 5.8 97 128 4.5 3 1.3 lakhs 142 915.5 small C
11 selvam 40 male 1315981 alcoholic 2 cms + no 1.1 78 55 2.7 1.4 88 000 145 606.9 small B
12 panchabhikesha 59 male 1383465 hepatitis B no + no 0.8 126 57 2.4 3 1 lakh 130 769.2 small B
13 manimeghalai 20 female 1383313 wilson's 3 cms no no 1.1 56 45 2.3 1.8 1.12 lakhs 150 746.6 large B
14 dhanamani 30 female 1383283 autoimmune 2cms no no 1.1 345 469 3.4 2.1 1.1 lakhs 150 733.33 large B
15 vanita 33 female 1383306 hepatitis B 2 cms no no 1.2 200 137 2.4 1.6 80 000 150 533 large B
16 santhappan 53 male 1380291 alcoholic no + no 1.2 234 143 4 1.9 1.43 lakhs 135 1059.2 NO VARICES A
17 shivaranjini 21 female 1383667 wilson's 1 no no 0.8 68 55 4 2.1 1.3 lakhs 124 NO VARICES A
18 muthukannu 33 male 1382462 alcoholic no + + 2.4 234 170 4 2 1.5 lakhs 110 1363.6 NO VARICES B
19 lakshmi 60 female 1383657 hepatitis B 2 cms + + 3 120 35 2 2.6 1 lakhs 130 769 large C
20 ali batcha 40 male 1354177 alcoholic 2 cms + + 11.8 450 260 1 3.8 66 000 148 445.9 large C
21 nagamani 54 male 1384420 alcoholic no no + 10.4 555 400 3.5 1.6 1.6 lakhs 120 1333.3 NO VARICES B
22 malliga 47 female 1384781 autoimmune 2 cms + no 1.2 280 200 3 2 1.2 lakhs 140 857.14 small B
23 sathish kumar 16 male 1377289 wilson's no no no 1.2 29 31 4.5 1.2 1.8 lakhs 120 1500 NO VARICES A
24 kannaiyan 40 male 1384777 alcoholic 6 cms + no 1.4 120 98 2 2.4 1.4 lakhs 170 823.5 small C
25 murugeshan 45 male 1385616 alcoholic 2 cms + + 8.2 230 140 3.8 2.8 1.1 lakhs 140 785.7 large C
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26 irulambal 50 female 1388106 cryptogenic 6 cms + no 0.8 120 100 3.6 1.8 1.8 lakhs 170 1058.8 NO VARICES B
27 sivasamy 35 male 1385745 alcoholic 5 cms no + 3.8 340 200 4 2.5 1.0 lakh 160 625 large C
28 Mohd. Amanulla 40 male 1385482 alcoholic no + + 1.8 268 200 4.8 1.4 1.35 lakhs 120 1125 NO VARICES A
29 durai 50 male 1383772 alcoholic 4 cms + + 2.2 58 45 4.6 2.2 90 000 160 562.5 large C
30 ramesh 27 male 1385843 alcoholic 3 cms no +
encephalo
pathy
6 380 290 3.4 3.8 1.2 140 857.1 small C
31 marudhamuthu 50 male 1387121 hepatitis B/C 5 cms no + 15.2 560 555 3 3.2 80 000 160 500 large C
32 sheik abdulla 42 male 1387164 alcoholic 7 cms + +
encephalo
pathy
3.8 200 180 2.4 3.8 80 000 180 444.4 large C
33 ayyadurai 55 male 1386657 hepatitis B no no no 1 75 45 4.8 1.6 1.2 lakhs 100 1200 NO VARICES A
34 vanita 27 female 1386781 hepatitis c 1 cm + + 5.2 180 220 3 3 1 lakh 140 714.2 small C
35 albert 35 male 1387551 alcoholic no + + 2.8 268 200 5 2 1.2 lakhs 120 1000 NO VARICES B
36 velu 38 male 1387240 hepatitis B 2 cms + + SBP 3 180 140 2 3.2 1.1 lakhs 140 785.7 small C
37 parthiban 44 male 1387115 alcoholic no no + 4.8 280 160 5.5 1.8 1.45 120 1208.3 NO VARICES B
38 kumarselvam 35 male 1387543 alcoholic/hepat
itis c
1 cm + + 6 480 450 2.8 2.2 90 000 140 642.8 small C
39 sashikala 31 female 1379998 hepatitis c no no + 8.8 180 170 4.8 1.2 1.4 lakhs 130 1076.9 NO VARICES B
40 ravichandran 57 male 1379419 alcoholic 2 cms no no 1.2 280 250 4.2 1.8 1.1 lakhs 140 785.7 small A
41 annapan 45 male 1379766 alcoholic 4 cms + no 1.1 110 90 3 2.1 1.2 lakhs 150 800 small B
42 ganapathi 32 male 1377092 alcoholic 2 cms no + 3 120 90 4.8 1 1.5 lakhs 140 1071.4 NO VARICES A
43 velayutham 65 male 1381754 alcoholic no + no 0.8 200 180 3 4 70 000 120 583.3 large C
44 kaliyaperumal 50 male 1381778 alcoholic 2 cms no no 0.9 45 40 4.5 1.2 1.5 lakhs 138 1086.9 NO VARICES A
45 sriram 27 male 1381743 alcoholic 4 cms no + 3 333 320 2 2 1 lakh 150 666.6 large C
46 papathi 45 female 1394024 hepatitis B/C 5 cms no no 0.8 35 22 2 4 60 000 160 375 large C
47 ramalingam 43 male 1391466 alcoholic/hepat
itis c
no + + 4.2 68 60 3 3.1 90 000 125 720 small C
48 kalaiselvi 25 female 1379182 cryptogenic 1 cms no + 2.8 45 40 4.8 2.8 1.4 lakhs 140 1021.4 NO VARICES A
49 Jayasudha 26 female 1381235 hepatitis c 5 cms + + 3.8 230 200 2 3.2 1.4 lakhs 160 875 large C
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50 pugalselvi 25 female 1371182 cryptogenic 1 no + 2.8 312 288 4 1.6 1.43 lakhs 138 1021.4 NO VARICES A
51 jayendran 30 male alco/hepc 3 + + 3 423 400 3.5 2.4 1.2 140 873 large C
52 rajeshwari 35 female 1376209 cryptogenic no no no 1.2 39 36 4.5 1.6 1.4 130 1076.9 NO VARICES A
53 kumar 40 male alcoholic 2 cms + + 4.8 220 180 2 2 60 000 150 400 large C
54 arumugam 53 male alcoholic 1 cms + no 1.8 342 180 4 1.8 1.6 lakhs 130 1230.7 NO VARICES A
55 marudhamuthu 45 male alcoholic 3 + no 1.2 200 180 3 2 1.2 lakhs 150 800 large C
56 jayanthi 18 female wilson's 1 + + 3.2 112 78 3.5 1.8 1 l 135 740.7 small B
57 sabapathy
32 male alcoholic 2 + +
encephalo
pathy
1.8 330 280 2 3.1 1 lakh 148 666.6 large C
58 arunazaghi 20 female cryptogenic no + + 11.2 50 44 2.3 3.2 1lakh 110 909.09 small C
59 subramaniyan 55 male alcoholic/hep b 2 + + 4.8 260 240 3 3.6 90 000 140 642.8 large C
60 murugadass 58 male alcoholic 3 no + 2.6 130 75 3.5 2.1 1.2 lakhs 130 923 small B
PROFORMA 
 
 
NAME:                                          
AGE/SEX                               
 IP NUMBER 
 
COMPLAINTS: 
DURATION: 
PRESENCE OF BLEEDING  
              MANIFESTATIONS: 
 H/0 ALCOHOL INTAKE: 
H/0 BLOOD TRANSFUSIONS/ 
TATTOING/ IV DRUG ABUSE: 
H/O DISEASE IN SIBLINGS 
H/O OTHER MANIFESTATIONS 
 
ETIOLOGY: 
 
CLINICAL FEATURES: 
GENERAL EXAMINATION: 
PR:                                                    BP:      
  ICTERUS:                              OTHERS:    
 
PER ABDOMEN:  
                             SPLEENOMEGALY                              ASCITES 
   
OTHERS: 
 
INVESTIGATIONS-  
 
TOTAL BILIRUBIN:                                               
AST:                                               
ALT:  
SERUM ALBUMIN:  
PT-INR:   
PLATELET COUNT:                                                 
SPLEEN DIAMETER (USG): 
CHILD-PUGH’S SCORE: 
PLATELET COUNT/SPLEEN DIAMETER RATIO: 
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ABBREVIATIONS 
 
OV- oesophageal varices 
PSR- platelet count/spllen diameter ratio 
PT-INR- prothrombin time-international normalized ratio 
HCC- hepatocellular carcinoma 
ALD- alcoholic liver disease 
ADH- alcohol dehydrogenase 
ALDH- aldehyde dehydrogenase 
NAFLD- nonalcoholic fatty liver disease 
NASH- nonalcoholic steatohepatitis 
PBC- primary biliary cirrhosis 
PSC- primary sclerosing cholangitis 
AMA- antimitochondrial antibodies 
pANCA- perinuclear antineutrophil cytoplasmic antibody 
SBP- spontaneous bacterial peritonitis 
LFT- liver function test 
ALT- alanine aminotransferase 
AST-aspartate aminotransferase 
PT- prothrombin time 
MELD- model for end stage liver disease 
CT- computerized tomography 
HVPG- hepatic vein pressure gradient 
UGI SCOPY- upper gastro-intestinal scopy 
CE- capsule endoscopy 
EUS- endoscopic ultrasound 
USG- ultrasonography 
TE- transient elastography 
MRI- magnetic resonance imaging 
EST- endoscopic sclerotherapy 
EVL- endoscopic variceal ligation 
TIPS- transjugular intrahepatic portosystemic shunts 
SD- standard deviation 
  
  
 
 
  
 
 
 
 
 
 
 
 
Figure : 1 
Endoscopic image of OV at the gastroesophageal junction. 
 
  
        
 
 
 
 
 
 
Figure  2 : 
Small varices on UGI SCOPY.  
 
     
 
 
 
 
  
Figure  3 : 
Large varices on UGI SCOPY 
 
 
 
 
  
 
Figure  4 :  Azygos vein demonstrated by Doppler EUS. Red indicates 
cephalad blood flow 
 
 
Figure  5 : Grey-scale imaging showing an enlarged spleen, dilated splenic 
vein and splenorenal varices. Doppler imaging of the same patient confirms 
the presence of varices.  
 
                          
 
Fig. 6   Enhanced CT scan shows a lobulated contour of the liver, 
splenomegaly, portosystemic collaterals (red arrows), and ascites. There are 
enlarged hepatic arterial collateral vessels and thrombus within the portal vein 
(blue arrows)  
 
                                
                                   
Fig. 7    MRI of the portal venous system demonstrates extensive esophageal 
varices (arrows) in conjunction with splenic and gastric varices  
 
 
  
 
 
 
Fig. 8 : Endoscopic image showing large varices with red wale markings. 
        
 
                                       
Fig 9 : Endoscopic image showing varices with cherry red spots. 
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INTRODUCTION Oesophageal varices (OV) are one of the most common complications of portal
hypertension that accompanies liver cirrhosis. The prevalence of OV may range from 60% to 80% in
patients with cirrhosis, and the reported mortality from variceal bleeding is around 17% to 57% 1-4 .
The Baveno III Consensus Conference on portal hypertension recommends that all patients with
cirrhosis should undergo endoscopic evaluation for varices at the time of diagnosis 5 . To evaluate
the progression of this feature, it has been proposed to repeat endoscopy in patients with no varices
every 2-3 years and every 1-2 years in patients with small varices 6 . In a developing nation like ours
where there...
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